Skip to main content

InspireMD, Inc.

NSPR
Exchange
Nasdaq
Industry
Surgical & Medical Instruments & Apparatus
SEC CIK
0001433607

In the last 90 days, InspireMD, Inc. insiders filed 5 open-market purchases and 0 sales; 38 institutions reported holding it in 13F filings for Q3 2026, worth $14.6M in total; no superinvestor holds it.

Currency
USD
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Nov 17, 2026, 2:20 AM ET

Revenue flow, FY2025

Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.

Net loss for FY2025: $48.8M (543.3% of revenue).

Income statement

Each column is one fiscal year, newest first.

Income statement of InspireMD, Inc., annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
ReportedMar 18, 2026Mar 12, 2025–Mar 30, 2023–
Revenue$8.98M$7.01M$6.21M$5.17M$4.50M
Cost of revenue$6.33M$5.50M$4.40M$4.05M$3.74M
Gross profit$2.65M$1.51M$1.81M$1.12M$754.0K
Operating expenses$52.3M$35.0M$22.9M$19.8M$15.5M
Research and development$15.0M$13.6M$7.98M$7.81M$5.16M
Selling, general and administrative$20.7M$15.3M$11.1M$8.36M$7.41M
Operating income-$49.6M-$33.5M-$21.1M-$18.7M-$14.7M
Income tax$63.0K$59.0K$65.0K$28.0K$45.0K
Net income-$48.8M-$32.0M-$19.9M-$18.5M-$14.9M
EPS, basic$-0.76$-0.76$-0.82$-2.35–
EPS, diluted$-0.76$-0.76$-0.82––
Weighted shares, basic64.3M41.9M24.3M7.87M–
Weighted shares, diluted64.3M41.9M24.3M––
Margins and growth
Gross margin29.5%21.5%29.1%21.6%16.8%
Operating margin-552.6%-478.0%-340.7%-361.9%-327.4%
Net margin-543.3%-456.6%-321.0%-357.6%-331.9%
Revenue growth, year over year+28.1%+13.0%+20.0%+15.0%+80.9%

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of InspireMD, Inc., annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
ReportedMar 18, 2026Mar 12, 2025–Mar 30, 2023–
Cash and equivalents$8.94M$18.9M$9.64M$4.63M$12.0M
Short-term investments$45.3M$15.7M$29.4M––
Accounts receivable$2.17M$1.57M$1.80M$1.03M$1.22M
Inventory$3.40M$2.57M$2.11M$1.62M$1.14M
Total current assets$61.5M$40.5M$44.2M$21.3M$37.1M
Property, plant and equipment$3.58M$2.37M$1.06M$917.0K$632.0K
Total assets$69.4M$46.8M$47.6M$24.7M$39.7M
Total current liabilities$10.7M$7.68M$6.02M$5.07M$4.35M
Total liabilities$14.2M$10.7M$8.14M$7.26M$6.18M
Shareholders' equity$55.2M$36.1M$39.5M$17.4M$33.5M

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of InspireMD, Inc., annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
ReportedMar 18, 2026Mar 12, 2025–Mar 30, 2023–
Operating cash flow-$35.1M-$21.9M-$16.4M-$15.5M-$13.2M
Capital expenditures$1.66M$1.40M$381.0K$473.0K$344.0K
Free cash flow-$36.8M-$23.3M-$16.8M-$16.0M-$13.6M
Depreciation and amortization$476.0M$280.0M$232.0M$188.0K$161.0K
Stock-based compensation$12.3M$10.1M$4.49M$2.35M$1.58M
Investing cash flow-$30.6M$12.6M-$16.1M$8.44M-$22.5M
Financing cash flow$55.6M$18.5M$37.5M-$140.0K$35.0M
Net change in cash-$9.98M$9.28M$5.01M-$7.37M-$641.0K
Ratio
Stock-based compensation, % of revenue137.3%144.6%72.4%45.5%35.1%

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for InspireMD, Inc. by cover date
Cover dateShares outstandingChange in a yearFiling
Nov 16, 202654.1M+27.7%SEC
Aug 14, 202646.5M+11.4%SEC
May 7, 202646.8M+52.9%SEC
Mar 18, 202646.8M+57.6%SEC
Nov 10, 202542.4M+62.4%SEC
Aug 4, 202541.7M+62.3%SEC
May 8, 202530.6M+22.9%SEC
Mar 12, 202529.7M+26.6%SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-15 in Q2 2021.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.